Indicator Explainer
HBV DNA
Quantitative marker of hepatitis B virus replication used in treatment decisions and monitoring.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Measured in chronic hepatitis B management to assess replication level, guide therapy initiation, and monitor response or relapse.
Reading results
Reported in IU/mL; values are interpreted alongside serology and liver assessments by the treating clinician. Different assays have different dynamic ranges and detection limits, so cross-platform comparisons need care.
Questions to ask a professional
- What is the reportable range of this assay?
- How are results below the detection limit reported?
References
- Hepatitis B: A Review. — JAMA, 2026 (PMID doi: 10.1001/jama.2026.6070)
- Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. — JAMA, 2006 (PMID )
- 4-Diketopyrrole-2-carboxamide derivatives affecting HBV capsid assembly: structure-activity relationship around the GLP-26 scaffold. — Org Biomol Chem, 2026-10-09 (PMID 42851025; literature)
- Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach. — Virus Res, 2026-10-03 (PMID 42829048; literature)
- Integrative characterization of human hepatocellular carcinoma-derived organoids and their HBV-associated biology. — Clin Transl Med, 2026-10-01 (PMID 42834792; literature)
- Revisiting Liver Monitoring During Methotrexate Therapy in Rheumatoid Arthritis: Implications of HBV Reactivation, MASLD, and Non-invasive Fibrosis Assessment. — Mod Rheumatol, 2026-10-01 (PMID 42820996; literature)
- Association Between EBV Lytic Replication and Liver Injury in Patients With HBeAg-Negative Chronic HBV Infection. — J Med Virol, 2026-10-01 (PMID 42808824; literature)
- Case Report: Cryoglobulinemic Vasculitis Relapse With Peripheral Neuropathy During HDV-RNA Positivity Despite HBV-DNA Suppression. — Int J Rheum Dis, 2026-10-01 (PMID 42775503; literature)
- Association of nucleos(t)ide analogue treatment history with mortality in HBV-DNA-positive HBV-ACLF: a multicenter cohort study. — Front Immunol, 2026-09-23 (PMID 42846587; literature)
- Combined RNA- and DNA-targeting CRISPR ribonucleoproteins enhance suppression of HBV transcripts. — Front Genome Ed, 2026-09-23 (PMID 42845841; literature)
- Association Between HIV-1 RNA Detection Status and HBV DNA Detection: A Patient-Level Retrospective Longitudinal Molecular Study from Istanbul, Türkiye. — Diagnostics (Basel), 2026-10-04 (PMID 42882369; literature)